Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
MRSN | US
0.08
3.92%
Healthcare
Biotechnology
30/06/2024
04/10/2024
2.12
2.06
2.17
2.00
Mersana Therapeutics Inc. a clinical stage biopharmaceutical company develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660 a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056 an immunosynthen ADC. It has a research and development collaborations with Janssen Biotech Inc. and Merck KGaA as well as collaboration agreement with Asana BioSciences LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics Inc. in November 2005. Mersana Therapeutics Inc. was incorporated in 2001 and is headquartered in Cambridge Massachusetts.
View LessStrength based on increasing price with high volume
Low Debt to Asset (< 0.2)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
91.7%1 month
109.1%3 months
104.2%6 months
94.2%-
-
26.93
3.83
0.18
-2.20
3.22
-
-101.41M
260.07M
260.07M
-
-1.11K
-
-78.50
-213.33
8.72
11.05
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.45
Range1M
0.99
Range3M
1.07
Rel. volume
1.83
Price X volume
4.20M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Design Therapeutics Inc. Common Stock | DSGN | Biotechnology | 5 | 283.10M | 0.60% | n/a | 1.03% |
Rigel Pharmaceuticals Inc | RIGL | Biotechnology | 16.04 | 282.22M | -3.32% | n/a | -201.68% |
Abeona Therapeutics Inc | ABEO | Biotechnology | 6.46 | 279.81M | 3.69% | n/a | 31.63% |
Akebia Therapeutics Inc | AKBA | Biotechnology | 1.33 | 279.68M | -0.75% | n/a | -309.96% |
Nkarta Inc | NKTX | Biotechnology | 3.92 | 279.65M | -6.00% | n/a | 18.88% |
Editas Medicine Inc | EDIT | Biotechnology | 3.38 | 278.77M | 4.97% | n/a | 16.68% |
uniQure N.V | QURE | Biotechnology | 5.65 | 275.14M | 24.45% | n/a | 550.36% |
Vanda Pharmaceuticals Inc | VNDA | Biotechnology | 4.63 | 269.88M | 0.87% | n/a | 1.55% |
Genfit SA | GNFT | Biotechnology | 5.3861 | 268.80M | 4.67% | 13.90 | 104.08% |
Compass Therapeutics Inc. Common Stock | CMPX | Biotechnology | 1.93 | 265.55M | 0.52% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.02 | 57.65M | -4.67% | n/a | 268.43% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.89 | 19.79M | -2.50% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 1.0599 | 19.14M | -0.93% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.695 | 8.47M | -4.15% | n/a | 16.03% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.6199 | 5.90M | 6.82% | n/a | 19.98% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -2.20 | 0.76 | Cheaper |
Ent. to Revenue | 3.22 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 26.93 | 14.10 | Expensive |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 104.18 | 74.67 | Riskier |
Debt to Equity | 3.83 | -1.82 | Expensive |
Debt to Assets | 0.18 | 0.26 | Cheaper |
Market Cap | 260.07M | 3.73B | Emerging |